Fmr LLC Grows Position in BioNTech SE (NASDAQ:BNTX)

Fmr LLC grew its stake in BioNTech SE (NASDAQ:BNTX) by 797.8% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,299,929 shares of the company’s stock after acquiring an additional 5,598,190 shares during the quarter. Fmr LLC owned about 2.63% of BioNTech worth $748,243,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in BNTX. Planning Capital Management Corp lifted its holdings in BioNTech by 45,000.0% in the 3rd quarter. Planning Capital Management Corp now owns 451 shares of the company’s stock valued at $54,000 after purchasing an additional 450 shares in the last quarter. Blue Trust Inc. raised its position in shares of BioNTech by 491.1% in the third quarter. Blue Trust Inc. now owns 467 shares of the company’s stock valued at $55,000 after buying an additional 388 shares during the last quarter. EverSource Wealth Advisors LLC lifted its stake in shares of BioNTech by 106.3% during the first quarter. EverSource Wealth Advisors LLC now owns 489 shares of the company’s stock valued at $43,000 after buying an additional 252 shares during the period. GAMMA Investing LLC boosted its position in BioNTech by 86.9% during the second quarter. GAMMA Investing LLC now owns 512 shares of the company’s stock worth $41,000 after acquiring an additional 238 shares during the last quarter. Finally, Clear Harbor Asset Management LLC purchased a new stake in BioNTech in the 3rd quarter worth approximately $210,000. Institutional investors and hedge funds own 15.52% of the company’s stock.

BioNTech Stock Up 1.8 %

Shares of NASDAQ BNTX opened at $120.72 on Friday. The stock has a fifty day moving average price of $113.52 and a 200 day moving average price of $98.35. The company has a market cap of $28.94 billion, a P/E ratio of -57.49 and a beta of 0.26. BioNTech SE has a 12-month low of $76.53 and a 12-month high of $131.49. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX) last announced its earnings results on Monday, November 4th. The company reported $0.81 EPS for the quarter, beating the consensus estimate of ($1.26) by $2.07. The business had revenue of $1.24 billion for the quarter, compared to the consensus estimate of $514.08 million. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The company’s revenue was up 38.9% on a year-over-year basis. During the same period last year, the business posted $0.73 EPS. Research analysts anticipate that BioNTech SE will post -3.68 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the company. Berenberg Bank began coverage on BioNTech in a research note on Tuesday, November 19th. They set a “buy” rating and a $130.00 price target on the stock. TD Cowen reduced their target price on BioNTech from $132.00 to $122.00 and set a “hold” rating on the stock in a research report on Tuesday, November 5th. HSBC lifted their price target on BioNTech from $97.00 to $136.00 and gave the company a “buy” rating in a report on Monday, October 7th. Hsbc Global Res raised shares of BioNTech from a “hold” rating to a “strong-buy” rating in a research report on Friday, August 2nd. Finally, Bank of America upped their price target on shares of BioNTech from $125.00 to $150.00 and gave the stock a “buy” rating in a research report on Monday, September 16th. Four investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $138.67.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.